Myriad Genetics initiated by Merrill at neutral

Myriad Genetics Inc. was initiated by Merrill Lynch analyst David Munno at a neutral rating. Based in Salt Lake City, Myriad Genetics develops therapeutic and molecular diagnostic products for the treatment of various cancers, Alzheimer's and infectious diseases such as AIDS. Myriad Genetics shares Thursday slipped 2 cents, or 0.11%, to $17.43 on volume of 166,714 shares versus the three-month running average of 482,220.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.